Global Leadership Redefined: Andy Lin, Violist and Erhu Virtuoso, Unveils Vision for International Arts Academy in Asia

Dec. 11, 2025 - (SeaPRwire) - According to a report published by "The Icons", highly accomplished violist and Erhu Virtuoso Andy Lin successfully redefined the traditional image of leadership during his tenure as President of the World Taiwanese Chambers of Commerce – Junior Chapter (WTCCJC). By leveraging his unique blend of cultural artistry and human warmth, Lin injected a dynamic new spirit and connectivity into the international organization, and has now announced his next major endeavor: establishing a pioneering international academy of performing arts in Asia. Unlike previous WTCCJC presidents, who often came from established corporate backgrounds, Lin, a musician with a Doctor of Musical Arts degree, chose a distinctly different path. He emphasized that his approach was not dictated by titles or authority, but by treating every member with "artistic sensitivity and human warmth." Lin described his leadership style as akin to performing "chamber music," promoting coordination and collective decision-making over command and control, stating that true harmony arises from finding balance among diverse voices rather than relying on the loudest voice. Throughout his presidency, Lin traveled tirelessly across six continents, attending over thirty conferences and community events. Through impromptu musical performances and genuine one-on-one dialogue, he transformed WTCCJC into a comprehensive platform for cross-cultural exchange. Lin noted that this dedication to human connection and cultural engagement yielded the most fulfilling results, effectively turning a traditionally rule-bound organization into a bridge for shared vision and trust across continents. A significant outcome of his tenure was the creation and performance of "The Song of WTCCJC." This original composition quickly became a powerful, unifying symbol for the organization, with its opening line, "When stars gather from every corner of the world," serving as an emotional anchor for global members. Lin stressed that culture is a form of governance that unites people through shared emotions and symbols, making cross-continental collaboration effortless and leading to tangible results, such as connecting premium Vietnamese coffee to the New York market and supporting a Japanese medical-aesthetics brand's entry into the U.S. healthcare system. Following his successful term, Lin has shifted his focus to a new, major cultural initiative: establishing a world-class performing arts academy in Taiwan. This institution is planned to transcend conventional boundaries, integrating music, theatre, dance, interdisciplinary creation, and cultural technology. Lin's vision is to nurture creativity and cultural dialogue, making the academy a destination for global artists and effectively positioning Asia as a future center for the performing arts. He firmly believes that the school will become a meeting point for young artists from every nation, who will become "carriers of culture, taking Taiwan's stories back to the world—and bringing the world's colors into Taiwan." This culture-driven leadership model is set to continue its profound influence on the next generation of global leaders.

萬億工業賽道迎來「智慧樞紐」:解碼京東工業的價值邏輯

香港, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 京東工業(07618.HK)正式登陸港交所,為京東生態資本市場佈局再添重要一子。面對一個規模超過11萬億人民幣、但數字化滲透率僅個位數的廣闊藍海,京東工業的上市,本質上是將其多年沉澱的工業專業知識、獨特商業模式與扎實財務表現,置於資本市場的放大鏡下,接受長期價值的審視與定價。公開資料顯示,京東工業通過「太璞」這一「數」「實」結合的全鏈路數智化工業供應鏈解決方案,提供廣泛的工業品供應和數智化供應鏈服務,以滿足客戶的多樣化需求。根據灼識諮詢的資料顯示,按2024年交易額計,京東工業為中國MRO採購服務市場的最大參與者,同時也是中國工業供應鏈技術與服務市場最大的服務提供商。專業深耕破痛點 行業 Know-How 築護城河京東工業的價值基底,建立在深厚的工業供應鏈專業知識之上。這絕非簡單的商品線上化,而是對工業品參數標準化、採購流程數字化、履約體系智能化的深刻理解與系統重構。受益於京東集團二十餘年管理複雜全鏈路供應鏈的深厚積澱,以及自身在工業領域的持續深耕與突破,京東工業積累涉足廣泛品類的深厚的產品領域知識,並將其系統化融入「太璞」解決方案之中。據了解,「太璞」已覆蓋從商品數智化、採購管理、智慧履約到運營服務的全鏈條,能夠為製造業、能源、交通等複雜行業的重點企業客戶,提供深度定制化的供應鏈優化方案。這種基於行業Know-how構建的專業壁壘,是競爭對手難以在短期內模仿和超越的,構成了公司長期價值的堅實內核。灼識諮詢資料顯示,2024年,公司在中國的工業供應鏈技術與服務市場擁有最廣泛的客戶覆蓋。2025年6月30日前的12個月內,京東工業服務著約1.1萬家重點企業客戶。2025年上半年,公司重點企業客戶包括約60%的中國《財富》 500強企業及逾40%的在華全球《財富》500強企業。這些對供應鏈穩定性、合規性有極高要求的巨頭選擇京東工業,本身就是對其專業服務能力最權威的背書。輕資產平臺撬動重工業生態 盈利路徑清晰在商業模式上,京東工業創新性地採用輕資產模式,徹底擺脫傳統貿易商「規模越大、管理越重」的增長瓶頸。公司通過其技術平台,智慧聚合客戶需求,並與上游十餘萬家製造商、分銷商和代理商的產能和庫存進行數字化連結與精准匹配,打造了行業領先的存貨周轉效率與管理能力。同時,其智慧履約系統整合了廣泛的第三方物流服務商,構建了一張彈性、高效的協同網絡。這種模式使得公司在業務規模快速擴張的同時,保持了優異的運營效率和健康的現金流。它本質上是用技術和數據驅動整個工業供應鏈的「存量資源」更高效地運轉,從而創造出巨大的增量價值。基於輕資產運營模式,京東工業打造了一個可擴展的商業模式,從而在工業供應鏈技術與服務市場建立了領先地位,並成功將業務版圖從通用MRO產品(廣泛運用於各行業應用場景下而設計及製造的非生產性物料,如工具、安防用品等)擴展到專業MRO產品(針對專業應用場景或需專業知識的產品,如化學品、儀器儀表、機器設備等),並正在向BOM產品(直接用於終端產品的生產物料,如電子元器件、緊固密封件)市場進一步滲透。數據顯示,2024 年中國 MRO 採購服務市場規模為人民幣 3.7 萬億元,而整個中國工業供應鏈市場規模則達到人民幣 11.4 萬億元,龐大的市場基盤為業務延伸提供了充足空間。與此同時,公司還將業務從國內擴展到特定海外市場,包括東南亞及若干其他有前景的地區,以支持重點企業客戶的海外擴張。財務數據是檢驗商業模式成功與否的最終尺規。2022年至2024年,公司營收從 141億元增長至204億元,複合年增長率達到20.1% ,2025 年上半年營收進一步增至 103 億元,擴張成果顯著;盈利水平亦同步提升,經調整淨利潤從2022年的7.1億元攀升至2024年的9.1億元,2025年上半年,公司經調整淨利潤達5.0億元,同比增長34.1%。隨著規模效應進一步釋放和海外業務的拓展提速,其盈利增長的能見度和確定性有望不斷增強。綜上所述,京東工業以專業深耕破局行業痛點,用模式創新打開價值空間,財務穩健增長,共同構成其長期投資價值的堅實支撐。此外,作為京東集團在產業端的重要佈局,京東工業共用「京東」的品牌信譽,能夠快速建立客戶信任;同时,京东工业可以高效利用集團在物流基礎設施、支付體系及底層技術方面的資源,強化服務保障。隨著上市後資本實力的增強與業務的持續擴張,公司在工業供應鏈數字化賽道的領先優勢將進一步擴大。對於著眼長期、聚焦價值的投資者而言,當前正是佈局這一工業供應鏈數智化龍頭的優質時機。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong’s exports are expected to grow by between 8% and 9% in 2026, according to figures releaased today by the Hong Kong Trade Development Council (HKTDC). The forecast forms part of the HKTDC’s annual Export Outlook report and follows on from the city’s better-than-anticipated 2025 export performance.For 2026, this sustained growth is set to be driven by robust demand for AI-related electronics products. According to the findings of the recently-released HKTDC 4Q25 Export Confidence Index, the majority of exporters (53.2%) see rising demand for AI/new technology-related electronic consumer goods as the factor most likely to boost their 2026 business. This is seen as crucial given that the electronics sector, overall, accounts for more than 70% of Hong Kong’s total export value.Heightened uncertainty giving way to greater clarityThese upbeat figures are remarkable given the high year-on-year comparison base from 2025. This is because many exporters sought to frontload orders in a bid to complete shipments before the imposition of the much-anticipated US tariffs.Detailing the upshot of the tariff-related trade upheavals in particular, Irina Fan, Director of HKTDC Research, said: “While 2025 proved to be a year of heightened uncertainty, 2026 should be a year of greater clarity on global trade. With the Chinese Mainland and the US having come to a trade agreement in November, – some four months after many other nations had struck their own deals with the Trump administration – US tariffs are no longer among Hong Kong exporters' three biggest 2026 concerns.”Fan did, however, acknowledge that uncertainties remain ahead. She said that as US imports from different countries are subject to different levels of tariffs, business leaders around the world will be looking to re-organise their activities to optimise any cost advantages.Outlining what this will mean within the Asia-Pacific region, Fan said: “Chinese Mainland exports to the US will be subject to 20% reciprocal tariff rate until November 2026 [1]. This comparatively low additional tariff puts China-based suppliers, many with more mature and highly productive supply chains, on par with their Southeast Asia counterparts, while giving them a significant advantage over any country subject to a higher tariff rate.”Multi-sector expectation of continued export expansionUnderpinning Hong Kong’s anticipated 2026 export expansion are the findings of the HKTDC Export Confidence Index 4Q25, which was also released today. The two key measures of this long-established quarterly metric –the Current Performance Index (51.4) and the Expectation Index (51.9) – have both stayed above the 50-point watershed level, a clear indication that future export growth is expected.Commenting on the findings of the 4Q25 survey, Kenneth Lee, Head of the HKTDC Research’s Special Project and Business Advisory Section, said: “When it comes to  expansion plans over the next two-year period, Asia remains very much the focus. For 42.0% of respondents, the Chinese Mainland was the highest priority market, followed by the rest of Asia (30.3%) and the ASEAN bloc (18.9%). By industry, exporters in almost every sector saw scaling up their activities on the Chinese Mainland as their priority.”Beyond the headline findings of the survey, a more detailed analysis highlights good news for Hong Kong exporters in terms of both individual market prospects and the likely future success of most of the city’s key industry sectors.Positive sentiments for major markets and key industry sectorsIn specific terms, turning to the Market Expectation Sub-Index, the Chinese Mainland (57.2) and the ASEAN bloc (57.0) are still considered to have significant growth potential. Predictably, this was less the case for the US (down 1.4 to 38.0), with the uncertainties in its trade environment continuing to unsettle Hong Kong exporters.Turning to individual industries, a number of sectors have expansionary expectations for the year ahead (i.e. had  a relevant index reading of 50 or more). Topping the list is Jewellery (54.8), followed by Electronics (52.4), Timepieces (51.6) and Equipment/Materials (51.1).Despite such overall positive sentiments, the survey also points out the possibility that a number of challenges may lie ahead. Most notably, it cited rising labour and production costs (53.9%), growing logistics challenges (38.8%) and declining overseas orders on account of the general economic slowdown (38.2%) as potential future concerns.[1] On top of Trump 1.0 tariffs of ~20% on averageReferencesHong Kong 2026 Export Outlook: Sustained AI Product Demand Set to Drive 8-9% Growth Over Coming Year:https://research.hktdc.com/en/article/MjE4ODc2Mzk2NwHKTDC Export Confidence Index 4Q25: End-of-Year Figures Indicate Positive Expansion Prospects:https://research.hktdc.com/en/article/MjE4ODYyNTQwNwHKTDC Research website: https://research.hktdc.com/en/ Photo download: https://bit.ly/4oJPrPRHKTDC Director of Research Irina Fan (right) and HKTDC Section Head, Special Project & Business Advisory, Kenneth Lee (left) announced the HKTDC Export Confidence Index for 2025’s fourth quarter at a press conference todayHKTDC Director of Research Irina FanHKTDC Section Head, Special Project & Business Advisory Kenneth LeeMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Navin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

國泰君安國際榮登《商業週刊》彭博綠金2026值得關注榜 – 綠色金融機構榜單

香港, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 近日,《商業週刊》彭博綠金2026值得關注榜單在上海正式發佈。國泰海通集團下屬公司國泰君安國際控股有限公司(「國泰君安國際」或「公司」,股份代號:1788.HK)憑藉在綠色金融領域的卓越表現與創新實踐,成功入選「綠色金融機構榜單」。國泰君安國際始終將綠色金融作為戰略發展的核心驅動力,系統構建了具有行業引領性的可持續發展金融體系。公司不僅將綠色理念全面融入投融資決策與業務運營,更通過創新產品與服務,積極推動低碳經濟轉型與長期價值共創。憑藉在綠色債券、碳資產管理和可持續投資等關鍵領域的深入實踐與突出成效,公司已贏得市場與監管機構的高度認可與持續信任。面向未來,國泰君安國際將進一步發揮專業優勢,持續拓展綠色金融產品矩陣,深化綠色金融工具創新與應用,不斷延伸綠色金融生態的廣度與深度,為經濟社會高品質發展注入持久綠色動能。彭博綠金隸屬於國際領先的媒體集團Bloomberg彭博,是全球及中國首個全面聚焦綠色經濟的媒體平台。近年來,彭博綠金推出多個具有行業影響力的權威榜單,積極引領並推動企業在可持續發展領域的卓越實踐。「綠色金融榜單」是彭博綠金首次推出的全新榜單,旨在響應國家綠色金融政策號召,推動金融機構與企業綠色轉型,助力實現「雙碳」目標。關于國泰君安國際國泰海通集團下屬公司國泰君安國際(股票代號:1788.HK),是中國證券公司國際化的先行者和引領者,公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地,幷在新加坡、越南和澳門設立子公司,業務覆蓋全球主要市場,爲客戶境外資産配置提供高品質、多元化的綜合性金融服務,核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前,國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級,MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級,同時其標普全球ESG評分領先全球84%同業。公司控股股東國泰海通證券(股票代號:601211.SH/2611.HK)爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

國泰君安國際蟬聯《信報財經新聞》上市公司卓越大獎

香港, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 由香港專業財經媒體《信報財經新聞》主辦的「上市公司卓越大獎2025」頒獎典禮在香港成功舉辦。國泰海通集團下屬公司國泰君安國際控股有限公司(「國泰君安國際」或「公司」,股份代號:1788.HK)憑藉卓越表現,再度榮獲「主板」類別大獎,蟬聯此項殊榮。近年來,國泰君安國際持續推動多元化發展戰略,堅持穩健經營與風險管控並重,不斷深化業務佈局、推動創新轉型,實現財富管理、企業融資、投資管理等核心業務協同並進,整體經營質效顯著提升。展望未來,公司將繼續秉持「穩中求進」的發展基調,致力於構建覆蓋多元客戶群體的全週期綜合金融服務平台,推動可持續的高品質增長,為股東創造長期回報。《信報財經新聞》創刊於1973年,是香港首份以財經新聞為主的中文報紙,在業界享有廣泛影響力與權威性。「上市公司卓越大獎」評選已連續舉辦十屆,依託《信報》獨家研發的EJFQ「信號」系統,依據皮爾托斯基分數、專業分析師推薦頻次、股價表現及財務指標四大核心準則篩選入圍企業,並由行業領袖、商會代表、專業顧問及評審委員會共同審核,評選出表現卓越的上市公司。該獎項以其公正、專業的評選機制,在資本市場獲得高度認可。關于國泰君安國際國泰海通集團下屬公司國泰君安國際(股票代號:1788.HK),是中國證券公司國際化的先行者和引領者,公司是首家通過IPO于香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地,幷在新加坡、越南和澳門設立子公司,業務覆蓋全球主要市場,爲客戶境外資産配置提供高品質、多元化的綜合性金融服務,核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前,國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級,MSCI ESG「A」評級, Wind ESG「A」評級及商道融綠ESG「A」評級,同時其標普全球ESG評分領先全球84%同業。公司控股股東國泰海通證券(股票代號:601211.SH/2611.HK)爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

SHENZHEN, Dec 11, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients. More Information about Y-3 for Injection The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects. The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability. On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent. About Stroke According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001. 2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

康哲藥業(0867)抗急性缺血性卒中創新藥注射用Y-3中國NDA獲受理

深圳, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 康哲藥業控股有限公司("康哲藥業")欣然宣佈,1類新藥注射用Y-3(擬定中文通用名:注射用洛貝米柳)("注射用Y-3"或"產品")新藥上市許可申請(NDA)已於2025年12月11日獲得中國國家藥品監督管理局(NMPA)受理。產品為一種擬用於急性缺血性卒中的腦細胞保護劑。注射用Y-3靶點明確,作用機制清晰,可發揮多重療效。注射用Y-3作為全球首個基於腦卒中病理過程重要靶點PSD95-nNOS和MPO開發的腦細胞保護劑,作用於缺血性腦卒中缺血級聯反應多個關鍵病理過程,通過多靶點高選擇性協同,更有利於發揮腦細胞保護作用。產品具有優異的治療缺血性腦卒中和潛在的預防卒中後抑鬱焦慮症狀的作用。注射用Y-3臨床數據優異,療效優異,安全性佳。產品中國II期臨床試驗研究結果表明,在發病48小時內的缺血性腦卒中患者中,使用Y-3 40mg 每日一次治療後,達到90天優良功能結局(mRS評分0~1分)的患者比例較安慰劑組顯著提高,率差達到16%。產品中國Ⅲ期臨床研究由首都醫科大學附屬北京天壇醫院任組長單位,于全國近40家研究中心納入發病時間≤48小時的急性缺血性腦卒中患者近1,000例,旨在評價注射用Y-3治療發病在48小時以內的急性缺血性腦卒中患者的有效性和安全性。Ⅲ期臨床研究達到主要療效終點,患者臨床獲益明顯,整體安全性良好。主要研究結果未來計劃在國際學術會議上公佈,整體研究將在國際學術期刊上發表。中樞神經系統(CNS)是康哲藥業的核心優勢領域之一,已逐步形成深度佈局。產品組合包括在售創新藥維圖可(地西泮鼻噴霧劑)、原研品牌藥黛力新(氟哌噻噸美利曲辛片)以及處於NDA審評中的改良型新藥ZUNVEYL(葡萄糖酸苯加蘭他敏腸溶片),已夯實市場基礎。注射用Y-3的加入,將進一步強化產品矩陣,在專家網絡與市場資源上產生高效協同。期待注射用Y-3早日上市,為中國缺血性腦卒中患者帶來療效優異、作用更全面的新一代腦細胞保護劑,並憑藉集團卓越的商業化經驗與合規高效的運營體系,加速推動創新療法惠及更多患者。關於注射用Y-3的更多信息急性缺血性腦卒中的病理過程高度複雜且相互關聯,臨床亟需多靶點多機制協同干預,以實現對複雜的缺血級聯反應的更有效調控,從而提高治療效果和患者生活質量。注射用Y-3可解離PSD95-nNOS耦聯,抑制MPO活性,還可增強α2-GABAA受體(一種具有抗抑鬱、抗焦慮功能的GABAA受體亞型)活性,通过這種多靶點高選擇性協同機制,有望實現"卒中治療與卒中後抑鬱焦慮預防"同步干預的技術突破,使注射用Y-3有望成為一種療效優異,作用更全面的新型腦細胞保護劑。於2024年第十屆歐洲卒中組織會議(ESOC 2024)上以口頭壁報形式發表的注射用Y-3治療急性缺血性卒中的II期臨床試驗研究結果表明,在發病48小時內的缺血性腦卒中患者中,使用Y-3(20mg、40mg、60mg,每日一次)治療後達到90天優良功能結局(mRS評分0~1分)的患者比例顯著高於安慰劑組(20mg: 67.8% vs 60.7%、40mg: 76.7% vs 60.7%、60mg: 70.0% vs 60.7%)。且產品在急性缺血性腦卒中人群的安全性與安慰劑相當,表現出良好的耐受性。於2023年8月24日,康哲藥業通過其全資附屬公司與一家以臨床需求為導向、創新與研發驅動的新藥企業南京寧丹新藥技術股份有限公司就產品簽署合作協議("協議")。根據協議,康哲藥業獲得產品在中國大陸、香港特別行政區、澳門特別行政區的獨家推廣權。協議期限為永久。關於腦卒中根據國家衛健委發布的《腦血管病防治指南(2024年版)》,我國每年新發卒中約394萬例,占全球新發病例三分之一,其中缺血性卒中占比約72%,年新發病例超280萬;現患病的卒中患者已超2,800萬人[1]。2021年中國死因監測數據顯示,卒中死亡占全國總死亡人數的23%[1]。過去三十年,我國卒中相關殘疾的疾病負擔持續加重,疊加人口老齡化加快等因素,未來卒中防控壓力將進一步增大,給患者家庭和社會帶來巨大挑戰[1]。此外,卒中後抑鬱和焦慮是卒中常見並發症,發病率分別達到約30%和25%[2],會影響患者神經功能恢複,甚至增加死亡風險,嚴重影響患者預後。注射用Y-3對廣大卒中患者長期神經功能改善和總體預後具有重大潛在價值,市場前景廣闊。關於康哲藥業康哲藥業是一家鏈接醫藥創新與商業化,把控產品全生命週期管理的開放式平台型企業,致力於提供有競爭力的產品和服務,滿足尚未滿足的醫療需求。康哲藥業專注於全球首創(FIC)及同類最優(BIC)的創新產品,並高效推進創新產品臨床研究開發和商業化進程,賦能科研成果向診療實踐的持續轉化,造福患者。康哲藥業聚焦專科領域,擁有被驗證的商業化能力,廣泛的渠道覆蓋和多疾病領域專家資源,核心在售產品已獲領先的學術與市場地位。康哲藥業圍繞優勢專科領域不斷縱深發展,以鞏固心腦血管/消化/眼科/皮膚健康業務競爭力,帶來專科規模效率,其中皮膚健康業務(德鎂醫藥)已成為其細分領域的龍頭企業,並擬於聯交所獨立上市。同時,康哲藥業持續推動研產銷全產業鏈在東南亞及中東區域運營發展,以獲取新興市場的增量,助力集團實現高質量可持續發展。參考文獻/資料1.中華人民共和國國家衛生健康委員會. 腦血管病防治指南(2024年版)[J]. 磁共振成像, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.2.陳杏雨, 呂小涵, 李瑞娜, 等. 卒中後焦慮[J]. 國際腦血管病雜誌, 2022, 30(2) : 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.康哲藥業免責與前瞻性聲明本新聞無意向您做任何產品的推廣,非廣告用途。本新聞不對任何藥品和醫療器械和/或適應症作推薦。若您想瞭解具體疾病診療信息,請遵從醫生或其他醫療衛生專業人士的意見或指導。醫療衛生專業人士作出的任何與治療有關的決定應根據患者的具體情況並遵照藥品說明書。由康哲藥業編制的此新聞不構成購買或認購任何證券的任何要約或邀請,不形成任何合約或任何其他約束性承諾的依據或加以依賴。本新聞由康哲藥業根據其認為可靠之資料及數據編制,但康哲藥業並無進行任何說明或保證、明述或暗示,或其他表述,對本新聞內容的真實性、準確性、完整性、公平性及合理性不應加以依賴。本新聞中討論的若干事宜可能包含涉及康哲藥業的市場機會及業務前景的陳述,該等陳述分別或統稱為前瞻性聲明。該等前瞻性聲明並非對未來表現的保證,存在已知及未知的風險、不明朗性及難以預知的假設。康哲藥業並不採納本新聞包含的第三方所做的任何前瞻性聲明及預測,康哲藥業對該等第三方聲明及預測不承擔責任。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

SHENZHEN, Dec 11, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.More Information about Y-3 for InjectionThe pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.About StrokeAccording to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Eisai Rated “A”, the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

TOKYO, Dec 11, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it has been selected for the highest-rated “A” List in the fields of Climate Change and Water Security for 2025 by the global environmental non-profit organization CDP.(1) This marks the second consecutive year the company has been named in both categories of the CDP’s A List.Based on Eisai’s Future Creation Strategy(2) (Sustainability Strategy), the company is committed to addressing material issues and social challenges over the mid- to long- term, with the aim of contributing to sustainable corporate growth and the sustainable development of society. In the field of environmental conservation, Eisai has identified “Business activities with consideration for the global environment” as one of our material issues. Based on the Eisai Network Companies Environmental Policy, Eisai is promoting responses to climate change and sustainable water use as environmental activities across the group.As part of its climate change response, Eisai is working towards the realization of a decarbonized society, including obtaining approval for the SBT 1.5'C target from the Science Based Targets (SBT) Initiative in FY2023, and participating in the Japan Climate Initiative (JCI) Race to Zero Circle, which calls for achieving net zero by 2050. Through these efforts, Eisai is contributing to the reduction of greenhouse gas emissions.(3) Regarding sustainable water use, Eisai has set its mid-term target to reduce water withdrawal across the company by 7%(4) by FY2030 compared to FY2023, promoting efficient use of water resources, including recycling of laboratory wastewater and rainwater. Please refer to Eisai’s website for more detailed information about its environmental activities.To realize the human health care (hhc) concept, conservation of the global environment is essential. Eisai is committed to empowering people to “realize their fullest lives” through initiatives addressing climate change and the promotion sustainable water use.(1) A non-profit organization headquartered in the UK. The organization operates the world’s only independent environmental information disclosure system(2) Please refer to Eisai Value Creation Report (https://www.eisai.com/ir/library/annual/pdf/pdf2025vcr.pdf)(3) Please refer to the following news release for details. EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION, AIMING TO ACHIEVE NET ZERO BY 2050 (https:/www.eisai.com/news/2024/news202412.html)(4) Per unit of salesMedia Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing

5N+ Purity and On-Spec EBC Confirm Lac Knife's Potential as a North American Source of Ultra-High-Performance Graphite ApplicationsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - December 11, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and innovator of next-generation battery technology, is pleased to announce that follow-on purification and elemental analysis of material from its Lac Knife deposit (concentrate Lot ID: GN25073005) achieved 99.9996 wt.% ("5N+") and an Equivalent Boron Concentration ("EBC") of 2.03 ppm, confirming the material is within nuclear-grade specification and meets the technical thresholds required for several high-value advanced materials markets.The test work, conducted using electrothermal purification with no halogen gases (e.g. chlorine) or acids, produced this ultra-pure result in two (2) hours, further validating a chemical-free, environmentally advantageous pathway compared to conventional purification methods. These results directly support Focus's ongoing engineering and scale-up programs funded under Natural Resources Canada's ("NRCan") Global Partnerships Initiative ("GPI"), under which the Company was awarded a non-repayable contribution of up to $14.1 million to accelerate North American capacity for clean, advanced material processing.Subsequent elemental analysis calculated in accordance with ASTM C1233-15: Standard Practice for Determining Equivalent Boron Contents of Nuclear Materials yielded an Equivalent Boron Concentration ("EBC") of 2.03 ppm (Table 1), which falls below the critical 3 ppm threshold often cited for nuclear-grade graphite applications. The calculated EBC value is the most critical test of purity for nuclear industry use.These results suggest that Lac Knife graphite has the potential to serve markets requiring ultra-high-purity large and jumbo flake natural graphite. Achieving both 5N+ purity and a high proportion of large-flake concentrate is uncommon in the natural graphite industry and may provide Focus with opportunities in markets historically reliant on synthetic graphite or otherwise inaccessible to peers. These findings are consistent with peer-reviewed research published in ACS Omega ("Ultrahigh Temperature Purification of Graphite for the Development of a Continuous Process," ACS Omega, 2025), conducted by American Energy Technologies Company ("AETC") and NRCan, which demonstrated that ultrahigh-temperature purification of natural Canadian graphite can produce materials exhibiting purity and crystallinity suitable for advanced applications. Focus's ongoing testwork indicates that residual impurities appear primarily on the surface of the graphite flake—as evidenced by ultra-fine features observed through scanning electron microscopy—suggesting that purification efficiency is strongly influenced by surface cleaning dynamics rather than structural defects within the carbon lattice.Dean Hanisch, Chief Executive Officer of Focus commented, "These results validate Lac Knife as one of the rare unique natural graphite deposits capable of competing in high margin advanced technological markets and as a potential alternative to synthetic materials that are more expensive and have a larger environmental impact. With support from Canada's Federal Government, through Natural Resources Canada's Global Partnerships Initiative, we are now positioned to accelerate our scale-up work and unlock commercial pathways across nuclear energy, defense systems, graphene production, and next-generation electronics."Lac Knife graphite's combination of ultra-high purity and large flake distribution positions it for a range of advanced industrial, clean energy, and high-technology applications.Unlocking Advanced Markets Beyond NuclearBeyond nuclear applications, the ultra-high purity and medium-grain morphology of Lac Knife graphite position the material as a strategic feedstock for several advanced technology markets facing supply shortages, performance bottlenecks, and increasing scrutiny over material purity.Graphene & Few-Layer Graphene (FLG) ProductionIn the graphene sector, precursor quality is the primary determinant of performance. Impurities commonly found in natural graphite—typically 0.5-1 microns in size, or roughly one thousand (1000) times thicker than a graphene layer—are known to disrupt electrical, thermal, and mechanical properties unless fully removed. Lac Knife's 5N+ purity eliminates these defects at the source, allowing the flake to exfoliate cleanly into high-value graphene structures.Peer-reviewed research published in Carbon ("Influence of graphite geography on the yield of mechanically exfoliated few-layer graphene," Carbon, 2023) demonstrates the significance of geological origin in FLG production. In follow-on AETC—Yale University testing based on the methodologies outlined in that study, Lac Knife graphite achieved a record-high few-layer graphene yield of 22% ± 3%, outperforming all other natural samples evaluated and showing exfoliation behavior that synthetic graphite could not replicate.Taken together, these results position Lac Knife as one of the few North American natural flake sources capable of supplying advanced graphene markets, including conductive coatings, EMI-shielding materials, flexible electronics, sensors, and next-generation energy storage systems.Defence: IR Obscuration & Countermeasure SystemsThe defence sector presents another major opportunity. Modern warfare increasingly requires materials capable of obscuring both visible and infrared signatures. Traditional obscurants—such as bronze flakes, titanium dioxide, and red phosphorus—pose toxicity, safety, and performance challenges. High-purity graphite and graphene derived from Lac Knife offer a lightweight, non-toxic, and thermally stable alternative capable of generating rapid-dispersion and longer-lasting obscurant clouds.These materials are applicable to 40 mm muzzle-blast cartridges, airburst obscuration rounds for UAVs and rotorcraft, countermeasure dispenser systems, and naval surface-ship defence platforms. The U.S. Department of War currently procures graphene-based obscurants at approximately US$30,000 per ton, reflecting both strategic importance and limited supply. Lac Knife's purity is essential here, as impurities directly interfere with graphene formation and degrade obscurant performance.Stealth Coatings & Electromagnetic Protection SystemsUltra-high purity graphite also plays a critical role in stealth coatings and electromagnetic protection systems. Engineered systems operating across the 400 MHz to 30 GHz spectrum require materials that deliver highly reproducible electrical conductivity, thermal stability, and particle uniformity.These coatings and composites are used in radar-absorbing structures for stealth UAVs, thermal-vision targeting systems, and a range of low-observable technologies. Because deviations in graphite purity can compromise system reliability or operator safety, defence and shielding markets pay substantial premiums—often up to US$50,000 per ton—for 5N-grade material. Lac Knife's combination of purity, consistency, and grain structure aligns closely with these stringent requirements and allows for further refinement into fine, superfine, ultrafine, or microfine grades without compromising integrity.Critical Infrastructure Hardening (HEMP, IEMI and Geomagnetic Storms)The same purity advantages extend into critical infrastructure protection. As governments and utilities work to harden electrical grids, substations, and 5G networks against high-altitude electromagnetic pulses (HEMP), intentional electromagnetic interference (IEMI), and severe geomagnetic storms, materials must perform reliably across high-frequency ranges and under extreme operating conditions.Graphite-based shielding and coatings designed for these systems rely on predictable, reproducible material behavior—standards that only ultra-high purity graphite can meet. Lac Knife's 5N+ output offers the reliability required for these mission-critical applications.Additional High-Value Markets Enabled by 5N+ PurityIn addition to these strategic sectors, Lac Knife's purity profile and particle characteristics also unlock potential in several high-value industries, including thermal management components for semiconductors and LEDs, high-pressure synthetic diamond production, PEM and SOFC fuel-cell bipolar plates, and laboratory-grade graphite consumables where contamination must be tightly controlled. In each of these markets, ultra-high purity reduces defects, increases stability, and improves overall system performance, enabling natural graphite to compete directly with synthetic alternatives.Next Steps in Technical ValidationFocus is advancing a comprehensive technical qualification program to further define Lac Knife's suitability for nuclear and advanced material markets. Ongoing nuclear graphite testing includes detailed characterization of particle size distribution, compressibility, electrical resistivity, and coefficient of friction—parameters that determine whether a graphite material can perform reliably under the thermal, mechanical, and irradiation stresses present in high-temperature reactor environments. The Company expects to fabricate and evaluate near-net-shape graphite bricks, an essential step toward assessing Lac Knife material in full-scale core component geometries and within ASME Division 5 design criteria.In parallel, Focus is extending its validation program—supported through NRCan's Global Partnerships Initiative ("GPI")—advanced materials markets. Current work programs under consideration include assessing Lac Knife graphite as a precursor for high-yield graphene, nano-wafer substrates, thin-film semiconductors, next-generation electronic components, and aerospace composites, including unmanned aerial systems (UAS). These sectors demand highly reproducible, ultra-high-purity carbon materials traditionally sourced from synthetic graphite. Early results indicate that Lac Knife's 5N+ natural graphite may offer a technically competitive—and potentially more sustainable—North American alternative to synthetic feedstocks across multiple high-value applications.ElementImpurity Limit (mg/kg)EBC FactorEBC CalculationAg0.050.00830.000415Al10.00010.0001B0.1210.12Ca0.360.00020.000072Cd50.31721.586Cl1.50.01340.0201Co0.050.00890.00445Cr0.120.00080.000096Cu0.250.00080.0002Dy0.050.08180.00409Eu0.10.4250.0425Fe0.210.00060.000126Gd0.054.39910.219955K0.60.00080.00048Li0.030.14390.004317Mn0.120.00340.000408Mo0.150.00040.00006Na0.0850.00030.0000255Ni0.180.00110.00198S1.40.00020.00028Si1.460.00010.000146Sm0.050.53360.02668Th0.010.00050.000005Ti0.530.00180.000954U0.050.00050.000025V0.080.00140.000112    Total  2.0277895 Table 1: EBC Calculation, Thermally Purified Lac Knife Lot ID: GN250730005Figure 1: Particle Size Distribution, Thermally Purified Lac Knife Lot ID: GN250730005To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/277711_279dc9a07490cbe0_001full.jpgTap DensityScott VolumeSurface AreaLOI    g/ccg/ccm2 /gWt. % C0.60.41.499.9996 Table 2: Data, Thermally Purified Lac Knife Lot ID: GN250730005% TileSize (um)D10105.2D50337.3D90673.8MV368.5 Table 3: Data (2), Thermally Purified Lac Knife Lot ID: GN250730005Qualified PersonDr. Joseph Doninger, Director of Technology and Manufacturing for Focus Graphite, is the Qualified Person ("QP") as defined under National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Dr. Doninger has reviewed and approved the technical information contained in this news release. Dr. Doninger is a chemical engineer and the developer or co-developer of multiple U.S., European, and Canadian patents relating to carbon processing technologies and purification equipment. He has authored or co-authored more than two dozen technical papers and studies on graphite composite anodes, carbon-based materials for electrochemical energy storage systems, and advanced graphite for lithium-ion batteries.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.com.LinkedIn: https://www.linkedin.com/company/focus-graphite/ X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated performance and downstream applicability of ultra-high-purity graphite derived from the Lac Knife project; the potential for 5N+ purification results and nuclear-grade Equivalent Boron Concentration ("EBC") values to be replicated at larger scale; the implications of testwork conducted under Natural Resources Canada's Global Partnerships Initiative ("GPI") and the expected outcomes of related engineering, scale-up, and validation programs; the ability of Lac Knife graphite to meet nuclear, graphene, defense, electromagnetic shielding, thermal management, semiconductor, and other advanced material specifications; the potential commercial pathways associated with supplying high-purity natural graphite as an alternative to synthetic graphite; and the Company's strategy to position itself within North American supply chains for clean energy, advanced manufacturing, aerospace, and critical infrastructure markets.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277711 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

康健醫療x輝瑞香港推動全民呼吸道健康教育

EQS via SeaPRwire.com / 2025-12-11 / 17:30 UTC+8 康健慈善基金捐贈20價肺炎球菌疫苗 東華三院協作接種 (香港 • 2025年12月11日)康健國際醫療集團有限公司(「康健醫療」)攜手輝瑞香港推動全民呼吸道健康教育。康健醫療今日宣佈,透過康健慈善基金,捐贈一批20價肺炎球菌結合疫苗(生產商:輝瑞),予東華三院服務的弱勢社群,醫社協作實踐社區健康防護。   康健醫療與輝瑞香港積極響應香港醫務衛生局《基層醫療健康藍圖》,聯合開展全民呼吸道健康教育,助力將市民健康觀念從「以治療為本」轉向「以預防為主」。與此同時,康健醫療將透過遍佈全港的龐大醫療中心網絡,便利公眾更容易獲取20價肺炎球菌結合疫苗保護。東華三院亦將作為關鍵的社區合作夥伴,負責妥善分配康健慈善基金捐贈的20價肺炎球菌結合疫苗,於旗下服務單位精準識別合適的受惠人士進行接種。   康健醫療、輝瑞香港與東華三院將緊密合作,貫徹康健慈善基金「以愛護航,健康共融」的理念,共同減輕弱勢社群的疾病負擔,並提升社區整體健康水平。   Photo caption: 康健醫療主席兼行政總裁蔡加讚先生,GBS,JP(中)、康健醫療副醫療總監古頌為醫生(右三)、康健醫療執行董事黃宇先生(右二)、康健醫療執行董事張霄雪女士(右一)、康健醫療營運總監陳振康先生(左一)、呼吸系統科專科黃錦祥醫生(左三)、輝瑞香港及澳門區基層醫療業務負責人兼營運負責人陳敏剛先生(右四)、輝瑞香港及澳門區策略醫療夥伴鄺梓良先生(左二),以及東華三院譚鑑標李慧翹醫療中心(北角)主管陳利醫生(左四),一同出席疫苗捐贈儀式,攜手推動全民預防健康,共建安全社區。 ~ 續 ~   康健醫療主席兼行政總裁蔡加讚先生,GBS,JP稱肺炎球菌感染對本港公共衛生構成威脅,尤以長者及弱勢社群影響顯著,全民呼吸道健康教育刻不容緩。康健醫療為此引進20價肺炎球菌結合疫苗,讓市民接種一劑即可獲得對20種血清型的廣泛保護。他又稱,康健醫療透過康健慈善基金,捐贈疫苗予東華三院推行醫社協作,是以實際行動關顧弱勢社群。輝瑞香港及澳門區基層醫療業務負責人兼營運負責人陳敏剛先生認同並表示,肺炎球菌疾病為香港社會帶來醫療負擔,深信市民需獲得全面血清型保護,期望透過合作提升公眾對肺炎球菌疾病的認知。東華三院譚鑑標李慧翹醫療中心(北角)主管陳利醫生感謝康健醫療與輝瑞香港對社區健康的投入,東華三院很榮幸成為社區合作夥伴,承諾將妥善運用康健慈善基金捐贈的疫苗,精準幫助有需要弱勢社群。   康健醫療副醫療總監古頌為醫生提醒,市民不應輕視肺炎的威脅。他指,據衞生署最新統計,肺炎是香港第二大殺手。2024年,在香港,肺炎導致超過11,000人死亡,僅次於癌症,比心臟病及腦血管疾病更加致命1。肺炎球菌是肺炎的常見致病原,已知的肺炎球菌血清型超過100種2,接種肺炎球菌疫苗是預防肺炎球菌疾病其中一種最有效的方法。呼吸系統科專科黃錦祥醫生表示,肺炎球菌經飛沫或接觸傳播,潛伏期短(約1-3天)3。其引起的肺炎初期症狀如發燒、咳嗽與流感相似,易誤判,且可能與流感同時感染,增加診治複雜性。肺炎球菌可導致中耳炎、鼻竇炎等較輕微疾病,但對高風險人群可能引發侵入性肺炎、菌血症、敗血症或腦膜炎等嚴重疾病3,4,5,病情可急劇惡化,危及生命。接種疫苗是最有效的預防方法,能顯著降低侵入性感染及重症風險3,4,5,研究亦顯示有助高風險人士降低心臟病發風險6。治療雖以抗生素為主,但抗藥性問題使治療更具挑戰3;他重申「預防勝於治療」對應對肺炎球菌感染尤其關鍵。   有關肺炎球菌結合疫苗的適應症及相關詳情,請向醫生查詢。   ~ 完 ~   關於康健醫療:以健康成就美好生活 康健國際醫療集團有限公司(股份代號3886.HK)是香港歷史最悠久、規模最大的上市醫療集團之一,亦是本地少數同時在香港及內地提供醫療保健服務的綜合醫療機構,擁有優質醫療資源和強大專業醫療團隊。旗下業務板塊包括:(i)於香港提供醫療服務;(ii)於香港提供醫療網絡管理服務;(iii)於內地提供醫院管理及健康管理服務;及(iv)於香港及內地提供醫療美容及美容保健服務。康健以健康成就美好生活為發展使命,致力成為扎根香港、覆蓋灣區、服務全國的國際一流醫療集團。如欲了解更多資訊,請瀏覽https://thmd.townhealth.com,或查看https://www.facebook.com/TownHealthMedicalHK。   關於康健慈善基金:緊貼社會所需 康健醫療將「企業社會責任」列入發展的其中一個重要方向,務求對持份者、社會及環境負責。近年,康健醫療透過不同形式支持本地慈善團體,為弱勢社群提供各類支援服務。至今,康健醫療已連續多年獲香港社會服務聯會嘉許為「商界展關懷」機構。2015年10月8日,康健醫療設立「康健慈善基金」,並以「支援弱勢社群」及「推廣健康生活」為主要工作方向。基金希望透過撥款,協助本地社會服務團體為基層市民推出直接相關的支援計劃,惠澤社群。   關於東華三院: 東華三院於1870年創辦,是本港歷史最悠久的慈善機構,提供醫療、教育、社會及公共服務,貫徹「救病拯危、安老復康、興學育才、扶幼導青」使命。醫療衛生服務方面,東華三院轄下有5間醫院(東華醫院、廣華醫院、東華東院、東華三院黃大仙醫院及東華三院馮堯敬醫院)、42個中西醫療衞生服務單位及1個社區藥房,提供中西醫藥、健康普查、電腦掃描、牙科及長者健康服務。東華三院一直致力擴展醫療衛生服務,迎合市民的醫療需要,並成立多個助醫計劃,資助有需要的市民接受醫療服務,保障市民健康。如欲了解更多資訊,請瀏覽www.tungwah.org.hk。   關於輝瑞:為患者帶來改變其生活的突破創新在輝瑞,公司通過科學和全球資源為人們提供治療方案,以延長其生命,顯著改善其生活。在醫療衛生產品的探索、研發和生產過程中,輝瑞始終致力於奉行嚴格的質量、安全和價值標準。公司在全球的產品組合包括創新藥品和疫苗。每天,輝瑞在發達和新興市場的員工都在推進人類健康,推動疾病的預防、治療和治癒,以應對挑戰這個時代的頑疾。輝瑞還與醫療衛生服務方、政府和社區合作,支持並促進世界各地的人們能夠獲得更為可靠和可承付的醫療衛生服務。這與輝瑞作為一家全球卓越的創新生物製藥公司的責任是一致的。175餘年來,輝瑞一直致力於為所有依賴公司的人帶來改變。如欲了解更多資訊,請瀏覽www.pfizer.com.hk,或查看www.youtube.com/c/pfizerhongkong。   關於20價肺炎球菌結合疫苗 20價肺炎球菌結合疫苗是輝瑞的新一代肺炎球菌結合疫苗,其中包括肺炎球菌13價結合疫苗[白喉CRM197蛋白] 中已包含的13種血清型(1、3、4、5、6A、6B、7F、9V、14、18C、19A、19F和23F)的莢膜多糖結合物。該疫苗還含有另外七種血清型(8、10A、11A、12F、15B、22F和33F)的莢膜多糖結合物,這些血清型可引起侵入性肺炎球菌疾病,並與高死亡率、抗生素耐藥性及/或腦膜炎相關。20價肺炎球菌結合疫苗是現有肺炎球菌結合疫苗中血清型覆蓋範圍最廣的疫苗,有助於對抗20種肺炎鏈球菌血清型。   肺炎球菌高風險群組包括3,4,5:          兒童          長者          其他人士:          曾患侵入性肺炎球菌病、腦脊液滲漏或裝有人工耳蝸          長期心血管疾病(高血壓而沒有併發症除外)、肺病、肝病或腎病          新陳代謝疾病包括糖尿病或肥胖(體重指數 30 或以上)          免疫力弱(因情況如無脾、人類免疫力缺乏病毒感染/愛滋病或癌症/類固醇治療引致)          長期神經系統疾病致危及呼吸功能、難於處理呼吸道分泌物、增加異物入肺風險或欠缺自我照顧能力 Centre for Health Protection. Number of Registered Deaths by Leading Cause of Death, 2001-2024. https://www.chp.gov.hk/tc/statistics/data/10/27/380.html Bertran, Marta et al (2024, March 27). Invasive pneumococcal disease 3 years after introduction of a reduced 1+1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study, The Lancet Infectious Diseases, Volume 24, Issue 5, 546 – 556. Centre for Health Protection. Pneumococcal Infection. https://www.chp.gov.hk/en/healthtopics/content/24/10584.html U.S. Centers for Disease Control and Prevention. Pneumococcal Disease. https://www.cdc.gov/pneumococcal/index.html Centre for Health Protection. Pneumococcal Vaccination. https://www.chp.gov.hk/en/features/108124.html Bettina Heidecker, Peter Libby, Vassilios S Vassiliou, François Roubille, Orly Vardeny, Christian Hassager, Michael A Gatzoulis, Mamas A Mamas, Leslie T Cooper, Felix Schoenrath, Marco Metra, Offer Amir, Scott D Solomon, Ulf Landmesser, Thomas F Lüscher. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement: With the contribution of the European Association of Preventive Cardiology (EAPC), the Association for Acute Cardio Vascular Care (ACVC), and the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 46, Issue 36, 21 September 2025, Pages 3518–3531. https://doi.org/10.1093/eurheartj/ehaf384   2025-12-11 此財經新聞稿由EQS via SeaPRwire.com轉載。本公告內容由發行人全權負責。瀏覽原文: http://www.todayir.com/tc/index.php

京東工業即將登陸港股:萬億賽道的長期領跑者

香港, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 工業供應鏈數智化領航者京東工業(7618.HK)近期完成招股,預期於12月11日登陸港交所,成為京東生態旗下第 6 家上市公司,開啟對接全球資本的新征程。暗盤階段,公司股價波動不大較為穩定,不過筆者認為,暗盤作為新股上市前的「預演場」,其價格受制於有限的流動性、短期情緒及部分套利資金行為,往往不能完全反映一家公司的內在價值與長期潛力。對於京東工業這樣一家紮根于中國龐大工業腹地、已構建起深厚護城河的產業領導者而言,短暫的暗盤「微震」,或許正是投資者摒棄噪音、聚焦其核心價值的絕佳時機。行業龍頭地位穩固 萬億賽道紅利盡顯當前,中國工業供應鏈正處在數字化轉型的關鍵拐點。據灼識諮詢預測,2024年中國工業供應鏈技術與服務市場規模為 0.7萬億元,預計到2029年達到 1.1 萬億元,2024-2029 年複合增長率高達9.8%。隨著工業企業降本增效需求的日益迫切,中國工業供應鏈市場數字化滲透率仍有巨大提升空間。在這一藍海市場,京東工業早已佔據行業金字塔尖的核心位置,無疑將成為這一趨勢的最大受益者。其通過「太璞」這一「數」、「實」結合的全鏈路數智化工業供應鏈解決方案,推動工業供應鏈的數字化轉型,助力客戶實現保供、降本、增效及合規。按 2024 年交易額計算,公司穩居中國工業供應鏈技術與服務市場榜首。在競爭更為激烈的 MRO 採購服務領域,其龍頭地位同樣無可撼動,2024年交易額為第二名的近三倍。在高度分散、傳統冗長的工業供應鏈領域,這一市場份額和領先優勢的建立,本身就證明了其模式的有效性和強大的客戶認可度。供給端,截至2025年上半年底,京東工業已整合 15.8 萬家供應商,構建起覆蓋 80 個產品類別的超 8110 萬 SKU 龐大供給體系。客戶端,截至2025年6月底的過去12個月,京東工業服務著約 1.11 萬重點企業客戶,更囊括了 60% 的中國 《財富》 500 強和 40% 的在華全球《財富》500 強企業,廣泛的客戶基礎構築了穩定的增長基本盤。数智化三重壁垒 打造稳固竞争優勢如果說行業地位是京東工業的「硬名片」,那麼數智化供應鏈體系就是其最深的「護城河」。京東工業的「太璞」解決方案,深入客戶採購戰略規劃、供應商管理、履約運營乃至合規管控等各個環節。它不僅提供商品,更提供採購諮詢、交易平台服務、廣告服務等技術與服務。這種深度賦能,使其從賺取商品差價的「貿易商」,轉型為説明客戶優化整體供應鏈效率、節省綜合成本的「合作夥伴」,商業模式的層次和利潤空間更為豐厚。輕資產運營模式更讓公司實現了規模與利潤的雙贏。通過數智化連結終端需求與供應端產能,部分訂單直接由供應商發貨,既整合了第三方履約能力,又減少了物流資產投入。這一模式推動公司盈利快速改善,從 2022 年的經調整淨利潤約 7.1億元,到 2023 年8.2億元,再到2024 年增長至 9.1億元,2025 年上半年經調整淨利潤同比再增 34%,達到5.0億元,經調整淨利率同比增加0.5個百分點,盈利能力持續提升。與此同時,京東工業正以技術與業務雙輪驅動拓展增長邊界,在技術端,持續迭代工業大模型應用,深度賦能商品治理、需求預測等關鍵環節,進一步強化端到端智能解決方案能力;在國際業務方面,依託現有資源優勢,積極拓展海外市場,復制國內成熟數智化供應鏈模式,對接全球工業資源構建跨境服務網絡,挖掘萬億級跨境工業供應鏈服務潛力。從行業發展趨勢來看,工業供應鏈的數位化、智慧化是不可逆轉的潮流。京東工業在萬億賽道的龍頭地位、數智化構建的核心壁壘、持續改善的盈利質量,以及背後中國工業供應鏈轉型升級的時代紅利,共同構成了其長期投資價值的堅實基礎。隨著公司上市後業務的持續推進與價值的逐步兌現,市場終將重新認知這家工業供應鏈巨頭的成長潛力。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Nasdaq Verafin Joins Global Anti-Scam Alliance

THE HAGUE, NETHERLANDS, Dec 10, 2025 - (ACN Newswire via SeaPRwire.com) - The Global Anti-Scam Alliance (GASA) is pleased to announce that Nasdaq Verafin has joined GASA as a Foundation Member, strengthening the global effort to combat scams, financial crime, and digital fraud. As fraud tactics continue to evolve across borders and digital channels, cross-sector collaboration has become essential to protecting consumers and building safer financial ecosystems.Nasdaq Verafin's participation marks a meaningful step forward in the shared mission to advance trust, transparency, and resilience across the globe. In addition to joining the global effort, Nasdaq Verafin will join both the Brazil and Mexico chapters of GASA to partner with stakeholders across the financial ecosystem in Latin America, bolstering regional initiatives to combat financial crime."Criminals are innovating at an unprecedented rate, taking advantage of information siloes and the shortcomings of legacy technology to avoid detection. We are at an inflection point in the fight against financial crime, one that requires the entire ecosystem to come together, leveraging the power of collective intelligence to strengthen our defenses and better protect consumers around the globe. We look forward to partnering closely with the Global Anti-Scam Alliance to share innovative solutions, intelligence, and global expertise to the unique challenges financial institutions in Brazil and Mexico face," said Mauriceo Castanheiro, Head of International Payments Fraud at Nasdaq Verafin.Nasdaq Verafin is a global leader in financial crime management technology solutions, trusted by more than 2,700 financial institutions around the globe. The company's innovative approach combines consortium data, AI, and machine learning to deter, detect, and prevent criminal activity. Nasdaq Verafin's consortium approach uncovers hidden risks across the financial system, leveraging data and insights from across 800 million counterparties to improve fraud detection and prevention while reducing false positives."Having Nasdaq Verafin join the Global Anti-Scam Alliance as a Foundation Member is a milestone for our organization and for the global fight against scams. Their deep expertise in leveraging technology to more efficiently and effectively detect criminal activity brings a new level of insight and influence to our mission. With Nasdaq Verafin's partnership, and their representatives joining the boards of our Brazil and Mexico Chapters, we are strengthening our ability to connect global knowledge with local action. Together, we can help shape stronger policies, accelerate industry collaboration, and build the foundations of a scam free future." said Jorij Abraham, Managing Director of GASA."The addition of Nasdaq Verafin as a Foundation Member is not only a milestone for the Brazil Chapter, it is a strong endorsement of the relevance of our market and the seriousness of the work we have been building from day one. We are starting our journey already alongside a globally recognized institution known for excellence, innovation, and a deep commitment to integrity. This partnership strengthens our ability to translate global expertise into local impact and accelerates our mission to raise the standard of collaboration in the fight against scams and financial crime in Brazil." said Renata Salvini, Chapter Director for Brazil."With 76 percent of Mexican adults victimized by scams and 139 billion pesos lost annually, according to the 2025 State of Scams in Mexico Report, 2026 will be devastating. AI democratized productivity but industrialized fraud, this isn't a prediction, it's a countdown. Combating this epidemic requires integrated defenses where early detection triggers coordinated action across digital platforms, telecommunications, finance, and authorities. Nasdaq Verafin's addition to GASA Mexico bridges the gap between technology and coordination. Without systemic collaboration, our economic system remains vulnerable. This strengthens our multistakeholder commitment to essential stability", added Sissi de la Peña, Chapter Director for Mexico.Through this partnership, Nasdaq Verafin executives will join the Chapter Advisory Boards of GASA Mexico and Brazil. As a Foundation Member, Nasdaq Verafin will collaborate with GASA and its members, bringing insights from more than two decades of stopping financial crime to develop innovative new strategies that protect consumers from fraud and scams.To learn more about Nasdaq Verafin's approach to financial crime detection and prevention, visit www.verafin.com.About the Global Anti-Scam Alliance (GASA)The Global Anti-Scam Alliance is a non profit organization whose mission is to protect consumers worldwide from scams. GASA brings together policymakers, law enforcement agencies, consumer authorities, NGOs, the financial sector, telecom operators, internet platforms, service providers, and cybersecurity organizations to share insights, uncover emerging scams, and promote coordinated action against fraud. Learn more at https://www.gasa.org.About Nasdaq VerafinNasdaq Verafin provides Financial Crime Management Technology solutions for Fraud Detection and Management, AML/CFT Compliance and Management, High Risk Customer Management, Sanctions Screening and Management, and Information Sharing. More than 2,700 financial institutions, representing 11 trillion dollars in collective assets, use Nasdaq Verafin to prevent fraud and strengthen AML/CFT efforts. Visit www.verafin.com to learn more.Cautionary Note Regarding Forward-Looking Statements:Information set forth in this release contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements can be identified by words such as "will", "may" and other words and terms of similar meaning. Such forward-looking statements include, but are not limited to, statements related to future actions and expected results. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These risks and uncertainties are detailed in Nasdaq's filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq's investor relations website at http://ir.nasdaq.com and the SEC's website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.© 2005 Nasdaq, Inc. The Nasdaq logo and the Nasdaq ‘ribbon' logo are the registered and unregistered trademarks, or service marks, of Nasdaq, Inc. in the U.S. and other countries. All rights reserved. This communication and the content found by following any link herein are being provided to you by Nasdaq, Inc. and/or certain of its subsidiaries (collectively, "Nasdaq"), for informational purposes only. Nasdaq makes no representation or warranty with respect to this communication or such content and expressly disclaims any implied warranty under law. At the time of publication, the information herein was believed to be accurate, however, such information is subject to change without notice. Nothing herein shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product, nor shall this material be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by Nasdaq.GASA Media ContactMetje van der MeerMarketing Directormetje.vandermeer@gasa.org+31 6 48456282Nasdaq Contact:Nick EghtessadCorporate Communicationsnick.eghtessad@nasdaq.com+1 929 996-8894SOURCE: Global Anti-Scam Alliance Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards

KUALA LUMPUR, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (the “Company” or “CBL”), the listing vehicle of the Banle Group (“Banle” or “the Group”) is honored to announce that Dr. Teck Lim Chia, Chairman and Chief Executive Officer of CBL International Limited, has been selected as an Awardee in the Directors of the Year Awards – Listed Companies Executive Directors category, presented by the Hong Kong Institute of Directors (HKIoD).This esteemed accolade follows a comprehensive evaluation by an independent panel of judges comprising senior business leaders, governance experts, and institutional investors. The award recognizes Dr. Chia’s outstanding contributions to corporate governance, exemplary board leadership, and his proven track record in driving sustainable value creation for shareholders and stakeholders.The HKIoD Directors of the Year Awards are among Asia’s most respected honors in corporate governance. Awardees are chosen based on demonstrated excellence in strategic oversight, ethical leadership, transparency, and long-term sustainable performance—all hallmarks of Dr. Chia’s tenure at CBL International. As Chairman and CEO, Dr. Chia has led the Group through a period of transformative growth while embedding governance excellence into the company’s core. Under his stewardship, CBL has strengthened its investor relations framework, enhanced ESG disclosures, deepened stakeholder engagement, and maintained rigorous compliance with international standards throughout its expansion across Asia Pacific, Europe, Central America and Africa.In accepting the award, Dr. Teck Lim Chia said: “I am deeply humbled and grateful to receive this prestigious recognition from the Hong Kong Institute of Directors. This honor belongs not to me alone, but to our entire board, management team, and employees who share a relentless commitment to integrity, innovation, and responsible growth. At CBL, we believe governance is not a box to check — it is the compass that guides every decision. I will continue to lead with purpose, accountability, and vision, always placing the long-term interests of our stakeholders first.”The Board of CBL International expressed its pride in Dr. Chia’s achievement: “Dr. Chia’s leadership has been instrumental in shaping CBL into a globally recognized, governance-forward enterprise. His ability to balance strategic ambition with disciplined oversight exemplifies what modern corporate leadership should be. We congratulate him on this well-deserved honor.”Photo caption: Dr. Teck Lim Chia (right), Chairman and CEO of CBL International Limited, honored at the Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).Photo caption: The trophy for Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications.For more information about our Company, please visit our website at: https://www.banle-intl.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CBL International Limited主席兼行政總裁謝威廉博士榮獲 香港董事學會「年度董事大獎」殊榮

吉隆坡, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 亞太地區領先的船用燃料物流公司萬利集團(「萬利」或「該集團」)之上市主體CBL International Limited(納斯達克股票代碼:BANL)(以下簡稱「公司」或「CBL」)宣布,集團主席兼行政總裁謝威廉博士在由香港董事學會(HKIoD)主辦的「年度董事大獎」中,榮獲「上市公司執行董事」類別大獎。此項殊榮經過由資深商業領袖、公司治理專家及機構投資者組成的獨立評審團全面評估後授予。該獎項表彰了謝威廉博士在公司治理方面的卓越貢獻、卓越的董事會領導能力,以及其在為股東及持份者創造可持續價值方面的傑出成就。香港董事學會「年度董事大獎」是亞洲最具聲望的公司治理榮譽之一。 獲獎者基於在策略監督、道德領導、透明度及長期可持續表現方面的卓越表現而獲選——這些正是謝威廉博士在CBL International內的核心特質。作為集團主席兼行政總裁,謝博士引領集團經歷轉型式增長,同時將卓越治理融入公司核心。在他的領導下,CBL加強了投資者關係框架,提升了環境、社會及管治(ESG)披露水平,深化了持份者參與度,並在集團業務拓展至亞太地區、歐洲、中美洲及非洲的過程中,始終保持嚴格的國際標準合規性。謝威廉博士在領獎時表示:「能夠獲得香港董事學會這一崇高榮譽,我感到謙卑與感激。此項殊榮不僅屬於我個人,更屬於我們整個董事會、管理團隊及全體員工,他們與我一樣,對誠信、創新及負責任增長懷有不懈承諾。在CBL,我們深信公司治理絕非簡單的合規檢查——它是指引每一項決策的指南針。我將繼續以目標、問責及遠見引領集團發展,始終將持份者的長期利益置於首位。」公司董事會表示:「謝威廉博士的領導力對塑造CBL成為全球認可、以治理為先的企業至關重要。他能夠在策略雄心與審慎監督之間取得平衡的能力,充分體現了現代企業領導者應有的風範。我們衷心祝賀他獲得此項實至名歸的榮譽。」圖片說明:CBL International Limited 主席兼行政總裁謝威廉博士(右),獲頒香港董事學會「年度董事大獎」之「上市公司執行董事」類別殊榮。圖片説明:香港董事學會「年度董事大獎」之「上市公司執行董事」獎杯關於萬利集團萬利集團成立於 2015 年,以CBL International Limited(納斯達克:BANL)在納斯達克股票市場上市。我們致力於為客戶提供一站式燃油供應服務,被業內稱為燃油供應服務商。我們主要通過當地實體供貨商為船舶提供燃油加注服務,遍布比利時、中國、香港、印度、日本、韓國、馬來西亞、毛里裘斯、巴拿馬、菲律賓、新加坡、台灣、泰國、土耳其和越南,共覆蓋65個港口。集團積極推動可持續燃料,並已取得ISCC EU和ISCC Plus認證。如欲瞭解更多信息,請到集團網站https://www.banle-intl.com瀏覽。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Since 2025, driven by both policy tailwinds and fundamental strengths, the innovative drug sector in the Hong Kong stock market has experienced a valuation recovery. Although it experienced some correction in the second half due to external environmental factors, its overarching growth logic remains intact. Institutional analysis indicates that innovative drugs continue to represent the clearest industry trend within the pharmaceutical sector, with promising development prospects ahead.Among the players, Cloudbreak Pharma (2592.HK), a biotech company focused on ophthalmology, has recently demonstrated strong stock performance. As of December 9, its share price closed at HK$8.24, having accumulated a gain of over 80% in approximately two weeks, and making it a standout "star stock" in the capital markets. This impressive performance is not coincidental but rather the inevitable result of multiple positive catalysts converging, including breakthroughs in its core product pipeline, enhancements to its global intellectual property (IP) layout, and an upgrade of its core management team.Securing Another Victory in Patent Layout, Accelerating Commercialization of Core ProductOn November 27, Cloudbreak Pharma's wholly-owned subsidiary, ADS Therapeutics LLC, successfully secured two core patents in Japan and Europe. Both patents relate to ophthalmic topical compositions and their uses for the core product CBT-009, laying a legal foundation for its global commercialization.As a novel atropine ophthalmic formulation for treating myopia in children and adolescents aged 5 to 19, CBT-009, with its unique non-aqueous formulation design, demonstrates potential advantages over traditional aqueous formulations in terms of drug stability, safety, and patient tolerability, positioning it as a potential best-in-class product. Currently, the product's development is progressing steadily. It received U.S. FDA approval to initiate Phase 3 clinical trial in September 2024. Juvenile animal toxicity studies in China commenced in February 2025, and preparations for Phase 3 clinical trial are actively underway.The grant of these patents in Japan and Europe not only strengthens the global IP portfolio for CBT-009, but will also accelerate its commercialization process. Leveraging patent protection, the Company has the potential to establish partnerships with global pharmaceutical giants to advance the product's production and distribution in key markets like Japan and Europe, accelerating global market penetration. Given the severity of the global adolescent myopia issue, CBT-009 is expected to become a core engine for the Company's future performance growth.Pipeline Progress Across Multiple Fronts; CBT-004 Advances Towards Phase 3Beyond CBT-009, another promising drug candidate from Cloudbreak Pharma, CBT-004, has also reached a significant milestone. As a potential first-in-class drug for vascularized pinguecula, CBT-004 uses Multi-Kinase Inhibitor targeting Vascular Endothelial Growth Factor Receptor (VEGFR) and Platelet-Derived Growth Factor Receptor (PDGFR). According to the Company's latest disclosures, CBT-004 yielded positive results in a Phase 2 clinical trial evaluating its safety and efficacy in treating pinguecula. The Company has begun advancing its Phase 3 clinical development and is scheduled to meet with the United States Food and Drug Administration (the “FDA”) on December 10 (Pacific Standard Time, PST) at an End-of-Phase 2 meeting to establish a regulatory pathway for potential approval.It is understood that there are currently no approved drugs globally specifically for treating vascularized pinguecula. Existing treatment options mostly offer temporary symptomatic relief, leaving significant unmet clinical needs. Should CBT-004 successfully complete development and gain approval, it would become the first targeted therapy, rapidly capturing market share with its unique efficacy advantages. This would create a new revenue stream for the Company while further solidifying its leading position in the field of ophthalmic innovative drugs.Strengthened Executive Team Elevates Commercialization CapabilitiesThe success of innovative drugs relies not only on R&D prowess but also on robust commercialization capabilities to realize their value. On December 1, 2025, Cloudbreak Pharma announced the official appointment of Mr. Michael Rowe as its new Chief Business Officer (CBO), injecting key momentum into the Company's global commercial strategy.Public information shows that Mr. Michael Rowe possesses substantial hands-on commercialization experience across senior management, marketing, sales management, and clinical operations. He is particularly skilled in driving organizational efficiency and achieving breakthroughs in innovative business areas. His industry resources and operational capabilities are expected to bring comprehensive enhancements to the Company.This executive appointment coincides with Cloudbreak Pharma’s core products entering a critical preparatory phase for commercialization. Mr. Michael Rowe's joining will strengthen the Company's business development capabilities in European and American markets, accelerating the construction of its global commercial footprint. Currently, through collaborations with companies such as Grand Pharmaceutical Group and Santen, Cloudbreak Pharma has established a commercialization foundation in Greater China and the Asia-Pacific region (excluding China). With the new CBO onboard, the Company is poised to further expand its global partnership network, optimize commercialization strategies, and provide robust support for the market entry of its multiple core products.With Sustained High Industry Growth, Valuation Re-rating Potential RemainsIn recent years, the global incidence of ophthalmic diseases has continued to rise. Conditions like pterygium and adolescent myopia affect hundreds of millions of patients, while the supply of innovative drugs in related treatment areas remains severely inadequate, indicating a vast unmet market need. Concurrently, governments worldwide are increasing support for pharmaceutical innovation, providing a favorable policy environment for high-quality innovative drug companies. Within the Hong Kong stock market, the innovative drug sector is experiencing a favorable trend of valuation re-rating. Companies with solid R&D pipelines, clear commercialization pathways, and core competitiveness are seeing gradually rising valuation expectations.As an innovative drug company dedicated to ophthalmology, Cloudbreak Pharma has built a rich pipeline covering 8 drug candidates targeting major diseases in both the anterior and posterior segments of the eye, forming a diversified product matrix. With steady progress in R&D and an increasingly refined global commercialization strategy, the Company already exhibits scarce growth attributes. The recent short-term surge in its stock price, catalyzed by multiple positive factors, is merely the beginning of value release. As these favorable initiatives are further implemented and pipeline value continues to be realized, Cloudbreak Pharma is poised to achieve dual enhancement in both performance and valuation. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

撥康視雲股價飆升逾8成 多重利好催化迎價值重估

香港, 2025年12月11日 - (亞太商訊 via SeaPRwire.com) - 2025年以來,港股創新藥板塊在政策面與基本面雙重驅動,迎來估值修復,雖下半年受外部環境影響有所回調,但整體增長邏輯未變。機構分析稱,目前創新藥仍是醫藥行業中產業趨勢最明確的主線,未來發展前景值得期待。其中,專注於眼科賽道的生物科技企業撥康視雲(2592.HK)近期股價表現強勁。截至12月9日,公司股價報收8.24港元,在兩周左右的時間內累計漲幅逾 8成,成為資本市場中備受矚目的「明星股」。這一亮眼表現並非偶然,而是撥康視雲核心產品研發突破、全球知識產權佈局完善、核心管理團隊升級等多重利好共振的必然結果。專利佈局再下一城 核心產品商業化進程加速11月27日,撥康視雲全資附屬公司 ADS Therapeutics LLC成功斬獲日本及歐洲兩項核心專利,均圍繞核心產品CBT-009 的眼科外用組合物及其用途展開,為該產品的全球商業化奠定了法律保障。作為用於治療5至19歲兒童及青少年近視的新型阿托品眼用製劑,CBT-009憑藉非水性製劑的獨特設計,在藥物穩定性、安全性及患者耐受性上均展現出對傳統水性製劑的潛在優勢,有望成為同類最佳產品。目前,該產品的研發進程穩步推進,2024 年 9 月獲得美國 FDA 批准開展 3 期臨床試驗,中國地區的幼年動物毒性研究也已於 2025 年 2 月啟動,3 期臨床試驗籌備工作正在積極推進中。此次日歐專利的獲批,不僅完善了CBT-009的全球知識產權矩陣,更將加速推進其商業化進程。依託專利保護,公司有望與全球大型製藥企業建立合作,推進該產品在日本、歐洲等關鍵市場的生產與分銷,加速全球市場滲透。考慮到全球青少年近視問題的嚴峻性,CBT-009有望成為公司未來業績增長的核心引擎。研發管線多點開花 CBT-004 衝刺三期臨床除了CBT-009,撥康視雲另一款潛力藥物CBT-004也迎來重要節點。作為針對血管化瞼裂斑的潛在同類首創藥物,CBT-004 採用多激酶抑制劑,靶向血管內皮生長因子受體及血小板衍生生長因子受體。根據公司最新披露的信息,CBT-004在治療瞼裂斑的安全性和有效性的二期臨床試驗取得積極結果。公司已著手推進其III期臨床開發,並將於12月10日(美國太平洋時間,PST)與美國藥監局(FDA)進行CBT-004第2期臨床試驗後的磋商,為潛在批准建立監管路徑。據了解,目前,全球尚無獲批的血管化瞼裂斑治療藥物,現有治療方案多為臨時緩解症狀的對症處理,臨床需求遠未得到滿足。一旦 CBT-004 研發成功並獲批上市,將成為首款針對性治療藥物,憑藉其獨特的療效優勢迅速搶佔市場份額,為公司帶來新的收入曲線,同時進一步鞏固公司在眼科創新藥領域的領先地位。高管團隊強勢升級 商業化能力再攀高峰創新藥的成功不僅依賴研發實力,更需要強大的商業化能力實現價值兌現。2025 年 12 月 1 日,撥康視雲宣佈新任首席商業官 MICHAEL ROWE 先生正式履職,為公司的全球化商業佈局注入關鍵動力。公開資料顯示,MICHAEL ROWE 先生在高管層管理、市場營銷、銷售管理及臨床運營等多個領域具備扎實的商業化實戰經驗,尤其擅長推動組織效能提升與創新業務突破,其行業資源與運營能力將為公司帶來全方位提升。此次高管任命恰逢撥康視雲核心產品進入商業化關鍵籌備期,MICHAEL ROWE的加盟將重點強化公司在歐美市場的業務拓展能力,加速全球化商業佈局的構建進程。目前,撥康視雲已通過與遠大醫藥、參天製藥等企業的合作,建立了在大中華區及亞太地區(除中國外)的商業化基礎,而隨著新任首席商業官的履職,公司有望進一步拓展全球合作網絡,優化商業化策略,為多款核心產品的市場落地提供有力保障。行業高景氣度持續 估值修復空間可期近年來,全球眼科疾病發病率持續上升,翼狀胬肉、青少年近視等疾病困擾著數以億計的患者,而相關治療領域的創新藥供給嚴重不足,市場存在巨大的未被滿足需求。同時,各國政府對醫藥創新的支持力度不斷加大,為優質創新藥企業提供了良好的政策環境。在港股市場,創新藥板塊正迎來估值修復的良好態勢。具備扎實研發管線、清晰商業化路徑及核心競爭力的企業,估值預期逐步提升。撥康視雲作為專注于眼科創新藥的創新藥企,目前已構建了涵蓋 8 款候選藥物的豐富管線,覆蓋眼球前後部主要疾病,形成了多元化的產品矩陣。目前,公司研發進展穩步推進,全球商業化佈局日趨完善,已然展現出稀缺的成長屬性。多重利好共振下,公司股價的短期飆升只是價值釋放的開始,隨著各項利好舉措的進一步落實和管線價值的持續兌現,撥康視雲有望實現業績與估值的雙重提升。 Copyright 2025 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com